Want to see JP:4594 full AI Analyst Report?
BrightPath Biotherapeutics Co.Ltd. (4594) AI Stock Analysis
BrightPath Biotherapeutics Co.Ltd.
(TSE/TYO:4594)
The score is driven primarily by weak fundamentals: highly unstable revenue, ongoing large operating losses, and sustained negative free cash flow that implies continued financing need. Technicals add further pressure with a clear downtrend (price below major moving averages and negative MACD). Valuation provides limited support because earnings are negative and no dividend yield is available.
BrightPath Biotherapeutics Co.Ltd. (4594) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 5.56B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.32M
- Price to Earnings (P/E)
- -3.1
- Beta (1Y)
- 0.78
- Revenue Growth
- -94.55%
- EPS Growth
- -6.51%
- Country
- Japan
- Employees
- 42
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
BrightPath Biotherapeutics Co.Ltd. Business Overview & Revenue Model
Company Description
BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for...
BrightPath Biotherapeutics Co.Ltd. Financial Statement Overview
Summary
Financial performance is weak overall. Revenue is extremely volatile and fell ~93% in the latest year, while EBIT and net losses remain large (roughly ¥1.1B–¥1.7B annually). The balance sheet is a relative strength with very low leverage, but persistent cash burn (FCF around -¥1.15B to -¥1.80B) keeps funding/runway risk elevated.
Income Statement
8Very NegativeBalance Sheet
62PositiveCash Flow
18Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 84.00K | 84.00K | 1.13M | 72.00K | 5.28M | 15.41M |
| Gross Profit | 55.00K | 55.00K | 1.10M | -341.00K | -13.33M | -23.03M |
| EBITDA | -1.30B | -1.30B | -1.15B | -1.17B | -1.47B | -1.45B |
| Net Income | -1.30B | -1.30B | -1.15B | -1.17B | -1.49B | -1.48B |
Balance Sheet | ||||||
| Total Assets | 2.60B | 2.60B | 1.12B | 1.23B | 1.70B | 2.77B |
| Cash, Cash Equivalents and Short-Term Investments | 2.16B | 2.16B | 810.47M | 1.06B | 1.53B | 2.31B |
| Total Debt | 0 | 0 | 25.00M | 112.50M | 0 | 87.50M |
| Total Liabilities | 236.41M | 236.41M | 195.62M | 251.27M | 133.91M | 239.73M |
| Stockholders Equity | 2.37B | 2.37B | 924.99M | 978.99M | 1.57B | 2.53B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.37B | -1.25B | -1.16B | -1.21B | -1.53B |
| Operating Cash Flow | 0 | -1.37B | -1.25B | -1.16B | -1.20B | -1.51B |
| Investing Cash Flow | 0 | -1.93M | -1.37M | -7.65M | -1.76M | -17.57M |
| Financing Cash Flow | 0 | 2.71B | 1.00B | 690.96M | 432.10M | 569.23M |
BrightPath Biotherapeutics Co.Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4594, the sentiment is Negative. The current price of 40.00 is below the 20-day moving average (MA) of 42.70, below the 50-day MA of 49.44, and below the 200-day MA of 55.86, indicating a bearish trend. The MACD of -2.74 indicates Negative momentum. The RSI at 33.83 is Neutral, neither overbought nor oversold. The STOCH value of 38.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4594.
BrightPath Biotherapeutics Co.Ltd. Peers Comparison
Overall Rating
JP:709666Neutral
JP:459348Neutral
JP:488045Neutral- JP:459444Neutral
JP:459938Underperform
JP:777626Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:7096 | 66Neutral | JPY 7.18B | 48.11 | ― | ― | 4.85% | -40.57% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4593 | 48Neutral | JPY 37.00B | 55.04 | ― | ― | -47.32% | ― |
| JP:4880 | 45Neutral | JPY 5.68B | 57.55 | ― | 1.75% | -9.94% | ― |
| JP:4594 | 44Neutral | JPY 5.56B | -3.13 | ― | ― | -94.55% | -6.51% |
| JP:4599 | 38Underperform | JPY 8.71B | -4.68 | ― | ― | ― | 4.85% |
| JP:7776 | 26Underperform | JPY 7.43B | -6.49 | ― | ― | -56.16% | 3.12% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4594 | BrightPath Biotherapeutics Co.Ltd. | 40.00 | -22.00 | -35.48% | |
| JP:4593 | Healios KK | 273.00 | -221.00 | -44.74% | |
| JP:4599 | StemRIM Inc. | 139.00 | -134.00 | -49.08% | |
| JP:4880 | CellSource Co., Ltd. | 286.00 | -225.00 | -44.03% | |
| JP:7096 | StemCell Institute | 701.00 | -109.00 | -13.46% | |
| JP:7776 | CellSeed Inc. | 188.00 | -249.00 | -56.98% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 21, 2026